The cerebrospinal fluid neurogranin/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer’s disease

Manuscript Number: 

16-0227R1

Author(s): 
Ellen De Roeck, Ann De Vos, Charles Duyckaerts, Sebastiaan Engelborghs, Erik Fransen, Dirk Jacobs, Tom Klewansky, Caroline Robberecht, Hanne Struyfs, Christine Van Broeckhoven, Eugeen Vanmechelen

Disclosures

Ellen De Roeck

  • Nothing to Disclose

Ann De Vos

  • Equity:
    I own shares of ADx NeuroSciences NV.

Charles Duyckaerts

  • Nothing to Disclose

Sebastiaan Engelborghs

  • Consulting Fees:
    was / is consultant for Innogenetics / Fujirebio Europe, Janssen, Lundbeck, Pfizer, Novartis, UCB, Nutricia / Danone
    Grants
    • Agency: 
      Janssen Pharmaceutica
      Dates: 
      1 OCT 2015 - ONG
    • Agency: 
      ADx NeuroSciences
      Dates: 
      1 OCT 2015 - ONG

Erik Fransen

  • Nothing to Disclose

Dirk Jacobs

  • Equity:
    I own shares of ADx NeuroSciences NV.

Tom Klewansky

  • Nothing to Disclose

Caroline Robberecht

  • Nothing to Disclose

Hanne Struyfs

  • Nothing to Disclose

Christine Van Broeckhoven

  • Grants
    • Agency: 
      Janssen Pharmaceutics INC Beerse, Belgium
      Dates: 
      2015-2016 Reserach Grant

Eugeen Vanmechelen

  • Equity:
    Co-founder of ADx NeuroSciences